Zander M., Madsbad S., Madsen JL, Holst JJEffect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study . Lancet. 2002;359:824-830.
2.
Larsen J., Hylleberg B., Ng K., Damsbo P.Glucagon-like peptide-1 infusion must be maintained for 24h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulfonylurea treatment. Diabetes Care. 2001;24:1416-1421.
3.
Kolterman OG , Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes . J Clin Endocrinol Metab.2003;88:3082-3089.
4.
Buse JB, Henry RR, Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
5.
DeFronzo RA, Ratner RE, Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28: 1092-1100.
6.
Kendall DM, Riddle MC, Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea . Diabetes Care. 2005;28:1083-1091.
7.
Blonde L., Klein EJ, Han J., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.
8.
Madsbad S., Schmitz O., Ranstam J., Jakobsen G., Matthews DR, NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care . 2004;27: 1335-1342.
9.
Harder H., Nielsen L., Tu DT, Astrup A.The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care.2004;27:1915-1921.
10.
Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes. In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association; June 9-13, 2006 ; Washington, DC. Abstract 115-OR.
11.
Vilsboll T. , Zdravkovic M., Le-Thi T., et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association ; June 9-13, 2006; Washington, DC. Abstract 2007-PO.
12.
Herman GA, Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther.2005;78:675-688.
13.
Bergman AJ, Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther.2006;28:55-72.
14.
Aschner P., Kipnes M., Lunceford J., Mickel C., Davies M., Williams-Herman D.Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta cell function after 24 weeks in patients with type 2 diabetes (T2DM). In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association; June 9-13, 2006 ; Washington, DC. Abstract 1995-PO.
15.
Ahrén B., Landin-Olsson M., Jansson PA, Svensson M., Holmes D., Schweizer A.Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab.2004;89:2078-2084.
16.
Dejager S., Lebeaut A., Couturier A., Schweizer A.Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association ; June 9-13, 2006; Washington, DC. Abstract 120-OR.
17.
Karasik A., Charbonnel B., Ji Liu J., Wu M., Meehan A., Meininger G.Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association ; June 9-13, 2006; Washington, DC. Abstract 501-P.
18.
Rosenstock J. , Baron M., Schweizer A., et al. Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM). In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 557-P.
19.
Stein P.Sitagliptin, a novel dipeptidyl peptidase-4 inhibitor, improves glycemic control in patients with type 2 diabetes. Late-breaking abstract. In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association; June 9-13, 2006; Washington, DC.
20.
Ahrén B., Gomis R., Standl E., Mills D., Schweizer A.Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.
21.
Fonseca V., Dejager S., Albrecht D., Shirt L., Schweizer A.Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM) . In: Program and Abstracts of the 66th Annual Meeting of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 467-P.
22.
Duttaroy A. , Voelker F., Merriam K., Zhang X., Ren X., Burkey B.The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases apoptosis . In: Program and Abstracts of the 65th Scientific Sessions of the American Diabetes Association ; June 10-14, 2005; San Diego, Calif. Abstract 572-P.
